Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Acute Coronary Syndrome | Research article

The role of MTHFR C677T and ALDH2 Glu504Lys polymorphism in acute coronary syndrome in a Hakka population in southern China

Authors: Jingyuan Hou, Zhixiong Zhong, Qiaoting Deng, Lifang Lin, Xing Zeng

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

Acute coronary syndrome (ACS) is the most serious type of coronary heart disease and is a global medical burden. The pathogenesis of ACS is very complex and still poorly understood. Epidemiologic studies have revealed that the manifestation of ACS are the results of the interactions between multiple environmental and genetic factors. The present study aimed to investigate the role of polymorphisms of MTHFR C677T and ALDH2 Glu504Lys as risk factors for ACS in a Hakka population in southern China.

Methods

Between September 1, 2015 and October 31, 2017, a total of 1957 individuals, including 860 ACS patients and 1097 controls were recruited. Blood samples were collected and genotypes were determined by DNA microarray chip method and direct sequencing method.

Results

For the MTHFR C677T polymorphism, frequencies of CC, CT, and TT genotypes were 53.60% versus 55.33, 39.53% versus 38.65 and 6.86% versus 6.02% in patients with ACS versus controls, respectively(p > 0.05). The differences in genotype frequencies between the ACS patients and controls in the three genetic model were not statistically significant. For the ALDH2 Glu504Lys polymorphism, the frequencies of ALDH2*1*1, ALDH2*1*2, and ALDH2*2*2 genotypes were 48.72, 42.67 and 8.6% in the ACS patients, respectively, while these were 53.33, 39.11 and 7.57% in the controls, respectively, showing no significant difference in the distribution of the ALDH2 genotype between the groups. Using the wild genotype ALDH2*1*1 as reference, relative risk analysis revealed a slightly increased risk for ACS in individuals with the ALDH2*1*2 plus ALDH2*2*2 genotypes (odds ratio (OR) = 1.203, 95% confidence interval (CI) = 1.006–1.438, p = 0.043). In a multivariate logistic regression model, even after adjusting for potential covariates, the association between ALDH2 *2 allele and ACS remained significant (OR = 1.242, 95% CI = 1.045–1.561, p = 0.038).

Conclusions

We present findings regarding the possible clinical impact of the ALDH2*2 variant on ACS patients in a Hakka population in southern China and our findings might help to stratify the high-risk ACS patients and implement appropriate strategies for this genetic subpopulation to ultimately guide the precision preventive procedures in the future.
Literature
1.
go back to reference Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256.PubMedPubMedCentralCrossRef Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256.PubMedPubMedCentralCrossRef
2.
go back to reference Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115(13):e356–75.PubMed Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115(13):e356–75.PubMed
3.
4.
go back to reference Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–94.PubMedCrossRef Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–94.PubMedCrossRef
5.
go back to reference Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.PubMedCrossRef Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.PubMedCrossRef
6.
go back to reference Guo R, Li Y, Wen J, Li W, Xu Y. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology. 2014;129(3):178–88.PubMedCrossRef Guo R, Li Y, Wen J, Li W, Xu Y. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology. 2014;129(3):178–88.PubMedCrossRef
7.
go back to reference Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.PubMedPubMedCentralCrossRef Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.PubMedPubMedCentralCrossRef
8.
go back to reference Yagi H, Komukai K, Hashimoto K, Kawai M, Ogawa T, Anzawa R, et al. Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol. 2010;55(3):345–53.PubMedCrossRef Yagi H, Komukai K, Hashimoto K, Kawai M, Ogawa T, Anzawa R, et al. Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol. 2010;55(3):345–53.PubMedCrossRef
9.
go back to reference Cheng X, Li W, Guo J, Wang Y, Gu H, Teo K, et al. Physical activity levels, sport activities, and risk of acute myocardial infarction: results of the INTERHEART study in China. Angiology. 2014;65(2):113–21.PubMedCrossRef Cheng X, Li W, Guo J, Wang Y, Gu H, Teo K, et al. Physical activity levels, sport activities, and risk of acute myocardial infarction: results of the INTERHEART study in China. Angiology. 2014;65(2):113–21.PubMedCrossRef
10.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.PubMedCrossRef Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.PubMedCrossRef
11.
go back to reference Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.PubMedCrossRef Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.PubMedCrossRef
12.
go back to reference Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25–33.PubMedCrossRef Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25–33.PubMedCrossRef
13.
go back to reference Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–30.PubMedPubMedCentralCrossRef Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–30.PubMedPubMedCentralCrossRef
14.
go back to reference Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood. 2003;101(7):2483–8.PubMedCrossRef Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood. 2003;101(7):2483–8.PubMedCrossRef
15.
go back to reference Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98(23):2520–6.PubMedCrossRef Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98(23):2520–6.PubMedCrossRef
16.
go back to reference Kerkeni M, Addad F, Chauffert M, Myara A, Gerhardt M, Chevenne D, et al. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann Clin Biochem. 2006;43(Pt 3):200–6.PubMedCrossRef Kerkeni M, Addad F, Chauffert M, Myara A, Gerhardt M, Chevenne D, et al. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann Clin Biochem. 2006;43(Pt 3):200–6.PubMedCrossRef
17.
go back to reference Tripathi R, Tewari S, Singh PK, Agarwal S. Association of homocysteine and methylene tetrahydrofolate reductase (MTHFR C677T) gene polymorphism with coronary artery disease (CAD) in the population of North India. Genet Mol Biol. 2010;33(2):224–8.PubMedPubMedCentralCrossRef Tripathi R, Tewari S, Singh PK, Agarwal S. Association of homocysteine and methylene tetrahydrofolate reductase (MTHFR C677T) gene polymorphism with coronary artery disease (CAD) in the population of North India. Genet Mol Biol. 2010;33(2):224–8.PubMedPubMedCentralCrossRef
18.
go back to reference Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149–55.PubMedCrossRef Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149–55.PubMedCrossRef
19.
go back to reference Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93(1):7–9.PubMedCrossRef Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93(1):7–9.PubMedCrossRef
20.
go back to reference Bosron WF, Li TK. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology. 1986;6(3):502–10.PubMedCrossRef Bosron WF, Li TK. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology. 1986;6(3):502–10.PubMedCrossRef
21.
go back to reference Guo YJ, Chen L, Bai YP, Li L, Sun J, Zhang GG, et al. The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: relation with endothelial ADMA levels. Atherosclerosis. 2010;211(2):545–50.PubMedCrossRef Guo YJ, Chen L, Bai YP, Li L, Sun J, Zhang GG, et al. The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: relation with endothelial ADMA levels. Atherosclerosis. 2010;211(2):545–50.PubMedCrossRef
22.
go back to reference Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, et al. Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet. 2009;73(Pt 3):335–45.PubMedPubMedCentralCrossRef Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, et al. Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet. 2009;73(Pt 3):335–45.PubMedPubMedCentralCrossRef
23.
go back to reference Zhong Z, Hou J, Li B, Zhang Q, Li C, Liu Z, et al. Genetic polymorphisms of the mitochondrial aldehyde dehydrogenase ALDH2 gene in a large ethnic Hakka population in southern China. Med Sci Monit. 2018;24:2038–44.PubMedPubMedCentralCrossRef Zhong Z, Hou J, Li B, Zhang Q, Li C, Liu Z, et al. Genetic polymorphisms of the mitochondrial aldehyde dehydrogenase ALDH2 gene in a large ethnic Hakka population in southern China. Med Sci Monit. 2018;24:2038–44.PubMedPubMedCentralCrossRef
24.
go back to reference Zhang X, Ye YL, Wang YN, Liu FF, Liu XX, Hu BL, et al. Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson’s disease in Han Chinese population. Neurobiol Aging. 2015;36(9):2660.e9–13.CrossRef Zhang X, Ye YL, Wang YN, Liu FF, Liu XX, Hu BL, et al. Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson’s disease in Han Chinese population. Neurobiol Aging. 2015;36(9):2660.e9–13.CrossRef
25.
go back to reference Li R, Zhao Z, Sun M, Luo J, Xiao Y. ALDH2 gene polymorphism in different types of cancers and its clinical significance. Life Sci. 2016;147:59–66.PubMedCrossRef Li R, Zhao Z, Sun M, Luo J, Xiao Y. ALDH2 gene polymorphism in different types of cancers and its clinical significance. Life Sci. 2016;147:59–66.PubMedCrossRef
27.
go back to reference Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008;321(5895):1493–5.PubMedPubMedCentralCrossRef Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008;321(5895):1493–5.PubMedPubMedCentralCrossRef
28.
go back to reference Mizuno Y, Hokimoto S, Harada E, Kinoshita K, Nakagawa K, Yoshimura M, et al. Variant Aldehyde Dehydrogenase 2 (ALDH2*2) is a risk factor for coronary spasm and ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(5):e003247.PubMedPubMedCentralCrossRef Mizuno Y, Hokimoto S, Harada E, Kinoshita K, Nakagawa K, Yoshimura M, et al. Variant Aldehyde Dehydrogenase 2 (ALDH2*2) is a risk factor for coronary spasm and ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(5):e003247.PubMedPubMedCentralCrossRef
29.
go back to reference Takeuchi F, Yokota M, Yamamoto K, Nakashima E, Katsuya T, Asano H, et al. Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet. 2012;20(3):333–40.PubMedCrossRef Takeuchi F, Yokota M, Yamamoto K, Nakashima E, Katsuya T, Asano H, et al. Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet. 2012;20(3):333–40.PubMedCrossRef
30.
go back to reference Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023–31.PubMedCrossRef Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023–31.PubMedCrossRef
31.
go back to reference Nakai K, Fusazaki T, Suzuki T, Ohsawa M, Ogiu N, Kamata J, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate increases risk of myocardial infarction and is correlated to elevated levels of homocysteine in the Japanese general population. Coron Artery Dis. 2000;11(1):47–51.PubMedCrossRef Nakai K, Fusazaki T, Suzuki T, Ohsawa M, Ogiu N, Kamata J, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate increases risk of myocardial infarction and is correlated to elevated levels of homocysteine in the Japanese general population. Coron Artery Dis. 2000;11(1):47–51.PubMedCrossRef
32.
go back to reference Helfenstein T, Fonseca FA, Relvas WG, Santos AO, Dabela ML, Matheus SC, et al. Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects. Clin Chim Acta. 2005;355(1–2):165–72.PubMedCrossRef Helfenstein T, Fonseca FA, Relvas WG, Santos AO, Dabela ML, Matheus SC, et al. Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects. Clin Chim Acta. 2005;355(1–2):165–72.PubMedCrossRef
33.
go back to reference Xuan C, Bai XY, Gao G, Yang Q, He GW. Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res. 2011;42(8):677–85.PubMedCrossRef Xuan C, Bai XY, Gao G, Yang Q, He GW. Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res. 2011;42(8):677–85.PubMedCrossRef
34.
go back to reference Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997;30(5):1206–11.PubMedCrossRef Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997;30(5):1206–11.PubMedCrossRef
35.
go back to reference Hsu LA, Ko YL, Wang SM, Chang CJ, Hsu TS, Chiang CW, et al. The C677T mutation of the methylenetetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51(1–2):41–5.PubMedCrossRef Hsu LA, Ko YL, Wang SM, Chang CJ, Hsu TS, Chiang CW, et al. The C677T mutation of the methylenetetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51(1–2):41–5.PubMedCrossRef
36.
go back to reference Lewis SJ, Ebrahim S, Davey SG. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331(7524):1053.PubMedPubMedCentralCrossRef Lewis SJ, Ebrahim S, Davey SG. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331(7524):1053.PubMedPubMedCentralCrossRef
37.
go back to reference Cai C, Xiao R, Van Halm-Lutterodt N, Zhen J, Huang X, Xu Y, et al. Association of MTHFR, SLC19A1 genetic polymorphism, serum folate, vitamin B12 and Hcy status with cognitive functions in Chinese adults. Nutrients. 2016;8(10):665.PubMedCentralCrossRef Cai C, Xiao R, Van Halm-Lutterodt N, Zhen J, Huang X, Xu Y, et al. Association of MTHFR, SLC19A1 genetic polymorphism, serum folate, vitamin B12 and Hcy status with cognitive functions in Chinese adults. Nutrients. 2016;8(10):665.PubMedCentralCrossRef
38.
go back to reference Gasparovic J, Raslova K, Basistova Z, Zacharova M, Wsolova L, Avdicova M, et al. Effect of C677T methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine levels in ethnic groups. Physiol Res. 2004;53(2):215–8.PubMed Gasparovic J, Raslova K, Basistova Z, Zacharova M, Wsolova L, Avdicova M, et al. Effect of C677T methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine levels in ethnic groups. Physiol Res. 2004;53(2):215–8.PubMed
39.
go back to reference Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, Shen J, et al. Interactions between genetic variants of folate metabolism genes and lifestyle affect plasma homocysteine concentrations in the Boston Puerto Rican population. Public Health Nutr. 2011;14(10):1805–12.PubMedPubMedCentralCrossRef Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, Shen J, et al. Interactions between genetic variants of folate metabolism genes and lifestyle affect plasma homocysteine concentrations in the Boston Puerto Rican population. Public Health Nutr. 2011;14(10):1805–12.PubMedPubMedCentralCrossRef
40.
41.
go back to reference Sun A, Zou Y, Wang P, Xu D, Gong H, Wang S, et al. Mitochondrial aldehyde dehydrogenase 2 plays protective roles in heart failure after myocardial infarction via suppression of the cytosolic JNK/p53 pathway in mice. J Am Heart Assoc. 2014;3(5):e000779.PubMedPubMedCentralCrossRef Sun A, Zou Y, Wang P, Xu D, Gong H, Wang S, et al. Mitochondrial aldehyde dehydrogenase 2 plays protective roles in heart failure after myocardial infarction via suppression of the cytosolic JNK/p53 pathway in mice. J Am Heart Assoc. 2014;3(5):e000779.PubMedPubMedCentralCrossRef
42.
go back to reference Jo SA, Kim EK, Park MH, Han C, Park HY, Jang Y, et al. A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men. Clin Chim Acta. 2007;382(1–2):43–7.PubMedCrossRef Jo SA, Kim EK, Park MH, Han C, Park HY, Jang Y, et al. A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men. Clin Chim Acta. 2007;382(1–2):43–7.PubMedCrossRef
43.
go back to reference Gu JY, Li LW. ALDH2 Glu504Lys polymorphism and susceptibility to coronary artery disease and myocardial infarction in east Asians: a meta-analysis. Arch Med Res. 2014;45(1):76–83.PubMedCrossRef Gu JY, Li LW. ALDH2 Glu504Lys polymorphism and susceptibility to coronary artery disease and myocardial infarction in east Asians: a meta-analysis. Arch Med Res. 2014;45(1):76–83.PubMedCrossRef
44.
go back to reference Xu F, Chen YG, Xue L, Li RJ, Zhang H, Bian Y, et al. Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome. J Cell Mol Med. 2011;15(9):1955–62.PubMedPubMedCentralCrossRef Xu F, Chen YG, Xue L, Li RJ, Zhang H, Bian Y, et al. Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome. J Cell Mol Med. 2011;15(9):1955–62.PubMedPubMedCentralCrossRef
45.
go back to reference Wada M, Daimon M, Emi M, Iijima H, Sato H, Koyano S, et al. Genetic association between aldehyde dehydrogenase 2 (ALDH2) variation and high-density lipoprotein cholesterol (HDL-C) among non-drinkers in two large population samples in Japan. J Atheroscler Thromb. 2008;15(4):179–84.PubMedCrossRef Wada M, Daimon M, Emi M, Iijima H, Sato H, Koyano S, et al. Genetic association between aldehyde dehydrogenase 2 (ALDH2) variation and high-density lipoprotein cholesterol (HDL-C) among non-drinkers in two large population samples in Japan. J Atheroscler Thromb. 2008;15(4):179–84.PubMedCrossRef
46.
go back to reference Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham offspring cohort. Circulation. 2001;104(12):1367–73.PubMedCrossRef Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham offspring cohort. Circulation. 2001;104(12):1367–73.PubMedCrossRef
47.
go back to reference Li SY, Ren J. Cardiac overexpression of alcohol dehydrogenase exacerbates chronic ethanol ingestion-induced myocardial dysfunction and hypertrophy: role of insulin signaling and ER stress. J Mol Cell Cardiol. 2008;44(6):992–1001.PubMedPubMedCentralCrossRef Li SY, Ren J. Cardiac overexpression of alcohol dehydrogenase exacerbates chronic ethanol ingestion-induced myocardial dysfunction and hypertrophy: role of insulin signaling and ER stress. J Mol Cell Cardiol. 2008;44(6):992–1001.PubMedPubMedCentralCrossRef
48.
go back to reference Li SY, Li Q, Shen JJ, Dong F, Sigmon VK, Liu Y, et al. Attenuation of acetaldehyde-induced cell injury by overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene in human cardiac myocytes: role of MAP kinase signaling. J Mol Cell Cardiol. 2006;40(2):283–94.PubMedCrossRef Li SY, Li Q, Shen JJ, Dong F, Sigmon VK, Liu Y, et al. Attenuation of acetaldehyde-induced cell injury by overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene in human cardiac myocytes: role of MAP kinase signaling. J Mol Cell Cardiol. 2006;40(2):283–94.PubMedCrossRef
Metadata
Title
The role of MTHFR C677T and ALDH2 Glu504Lys polymorphism in acute coronary syndrome in a Hakka population in southern China
Authors
Jingyuan Hou
Zhixiong Zhong
Qiaoting Deng
Lifang Lin
Xing Zeng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01410-7

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue